New Delhi: Noting that children usually have a mild disease but there is a need to develop COVID-19 vaccines for them, AIIMS Delhi Director Dr Randeep Guleria has said Bharat Biotech and other companies are doing trials at a very fast pace and hoped that data will lead to approvals so that there is a vaccine for children in the country by September-October. In an interview with media agencies, Dr Guleria said that Covaxin's data for children after completion of phase two or three trials is expected by September-October. Covaxin is an indigenous vaccine developed by Bharat Biotech in collaboration with ICMR.
"Children usually have the mild disease but we need to develop vaccines for children because if we have to control this pandemic everyone should be vaccinated. Bharat Biotech and other companies are doing trials at a very fast pace as parents have come forward with their children for the trials," he said. "One is hopeful that trial will be completed early and possibly with follow up of about two-three months, we shall have data by September. Hopefully, by that time, approvals will be there so that by September-October, we'll have vaccines from our country which we can give to children," he added. Dr Guleria said Bharat Biotech is conducting trials between the age group of 2 to 18 years and "this covers a wide spectrum".